Cagrilintide and pramlintide are both synthetic amylin analogs, but they were engineered a generation apart and solve different research problems. Pramlintide was designed to make amylin usable at all — a soluble, non-aggregating stand-in for a native hormone that otherwise self-destructs in solution. Cagrilintide was designed on top of that foundation to make amylin research last longer, trading pramlintide's minutes-scale pharmacokinetics for a profile measured in days.
Why amylin needs an analog in the first place
Native human amylin (islet amyloid polypeptide) is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. In its unmodified form it aggregates into amyloid fibrils almost immediately in solution — the same fibril structures found in diabetic islet tissue — which destroys its usefulness as a research tool. Both pramlintide and cagrilintide exist to work around this problem, using different structural strategies.
Pramlintide: solving aggregation, not duration
Pramlintide carries three proline substitutions at positions 25, 28, and 29 — borrowed from rat amylin, which does not aggregate — that break up the beta-sheet stacking responsible for fibril formation. The result is a stable, near-native-affinity amylin analog with a molecular weight around 3,950 Da. What it doesn't solve is duration: plasma half-life is roughly 50 minutes, so sustained receptor engagement in research protocols requires multiple daily doses or continuous infusion.
Cagrilintide: the same fix, plus a half-life extension
Cagrilintide (AM833) starts from the same proline-substituted, non-aggregating backbone and adds a C18 fatty-acid chain that binds reversibly to albumin in plasma — the same half-life-extension strategy used in semaglutide. That single modification stretches the half-life from pramlintide's roughly 50 minutes to approximately seven days based on published phase 1 pharmacokinetic data, enabling once-weekly dosing in research protocols instead of multiple daily injections.
What the difference means for study design
- Acute, tightly time-controlled protocols (e.g., isolating an acute glucagon-suppression or gastric-emptying response) favor pramlintide's short half-life, which allows a clean washout between conditions.
- Chronic or combination protocols — especially anything pairing amylin-receptor signaling with a once-weekly GLP-1 compound — favor cagrilintide, since its dosing interval matches longer-acting comparators and reduces handling frequency.
- Reversibility is the trade-off: pramlintide's effects clear within hours, while cagrilintide's persist for weeks once dosing stops, which has to be factored into crossover designs.
Shared receptor pharmacology
Both compounds act on amylin receptors — heterodimers of the calcitonin receptor (CTR) with RAMP1, RAMP2, or RAMP3 — without meaningful cross-activity at GLP-1 or insulin receptors at standard research concentrations. Cagrilintide's fatty-acid modification changes its pharmacokinetics, not its target selectivity, which is why the two compounds are often described as pharmacologically comparable but kinetically distinct.
Combination research context
Cagrilintide's once-weekly profile has made it the amylin component in combination research alongside semaglutide — studied together as CagriSema in published phase 1b and phase 3 trial data — where the two once-weekly compounds are examined on matched dosing schedules to separate amylin-receptor contributions from GLP-1-receptor effects. Pramlintide has also been studied alongside GLP-1 agonists, but its multiple-daily-injection requirement complicates protocol synchronization with once-weekly comparators; researchers typically resort to continuous infusion for that pairing instead.
Summary comparison
- Half-life: pramlintide ~50 minutes vs. cagrilintide ~7 days
- Dosing frequency (research use): pramlintide multiple times daily vs. cagrilintide once weekly
- Structural basis: shared proline substitutions (25, 28, 29); cagrilintide adds a C18 fatty-acid chain for albumin binding
- Receptor target: both are amylin-receptor (CTR/RAMP) agonists with minimal off-target GLP-1 or insulin receptor activity
- Best fit: pramlintide for acute, tightly washed-out designs; cagrilintide for chronic or combination protocols
Cagrilintide research peptide is available for laboratory use. For deeper background, see our cagrilintide mechanism of action and discovery and history articles, and semaglutide vs. tirzepatide for a related receptor-pharmacology comparison.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.